{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:19Z","timestamp":1740106999142,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This letter summarizes recommendations from the interdisciplinary working group of renal tumors (IAGN) of the German Cancer Society for the systemic treatment of advanced\/metastatic renal cell carcinoma in the context of the current SARS-CoV-2 pandemic<\/jats:p>","DOI":"10.1007\/s00432-020-03341-4","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T05:25:57Z","timestamp":1597901157000},"page":"3075-3078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systemic treatment of advanced\/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N)"],"prefix":"10.1007","volume":"146","author":[{"given":"Philipp","family":"Ivanyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Gr\u00fcllich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Kroeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Johannsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-3108","authenticated-orcid":false,"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the Interdisciplinary working group on renal tumors (IAG-N) of the German Cancer Socity (DKG)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"5","key":"3341_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2217\/imt-2020-0067","volume":"12","author":"M Bersanelli","year":"2020","unstructured":"Bersanelli M (2020) Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 12(5):269\u2013273. https:\/\/doi.org\/10.2217\/imt-2020-0067","journal-title":"Immunotherapy."},{"key":"3341_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O et al (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): PROGRESSION-free survival by independent review and overall survival update. Eur J Cancer [Internet] 94:115\u2013125","journal-title":"Eur J Cancer [Internet]"},{"issue":"8","key":"3341_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B et al (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 31(8):1030\u20131039. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.010","journal-title":"Ann Oncol."},{"key":"3341_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/GO.20.00097","volume":"6","author":"A Desai","year":"2020","unstructured":"Desai A, Sachdeva S, Parekh T, Desai R (2020) COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol 6:557\u2013559","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"3341_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V et al (2019) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet] 30(5):706\u2013720","journal-title":"Ann Oncol [Internet]"},{"issue":"5","key":"3341_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41571-020-0362-6","volume":"17","author":"TP Hanna","year":"2020","unstructured":"Hanna TP, Evans GA, Booth CM (2020) Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 17(5):268\u2013270","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"3341_CR7","first-page":"19","volume":"2045","author":"D Jones","year":"2020","unstructured":"Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K (2020) Comment Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer : the view from primary care. Lancet Oncol [Internet] 2045(20):19\u201320","journal-title":"Lancet Oncol [Internet]"},{"key":"3341_CR8","doi-asserted-by":"publisher","unstructured":"Lai AG, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH et al (2020) Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. https:\/\/doi.org\/10.1101\/2020.05.27.20083287","DOI":"10.1101\/2020.05.27.20083287"},{"issue":"3","key":"3341_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection a nationwide analysis in China. Lancet Oncol. 21(3):335\u2013337. https:\/\/doi.org\/10.1016\/S1470-2045(20)30096-6","journal-title":"Lancet Oncol."},{"issue":"6","key":"3341_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B et al (2018) Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 24(6):749\u2013757","journal-title":"Nat Med"},{"issue":"7","key":"3341_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J et al (2017) Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35(7):709\u2013717","journal-title":"J Clin Oncol"},{"issue":"2","key":"3341_CR12","doi-asserted-by":"publisher","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","volume":"8","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Powles T et al (2020) Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 8(2):e000891. https:\/\/doi.org\/10.1136\/jitc-2020-000891","journal-title":"J Immunother Cancer"},{"key":"3341_CR13","doi-asserted-by":"publisher","unstructured":"Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG (2017) Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer 64(12). https:\/\/doi.org\/10.1002\/pbc.26642","DOI":"10.1002\/pbc.26642"},{"issue":"12","key":"3341_CR14","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728","journal-title":"JAMA Oncol"},{"key":"3341_CR15","doi-asserted-by":"publisher","unstructured":"Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X (2020) Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.25972","DOI":"10.1002\/jmv.25972"},{"issue":"7","key":"3341_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","volume":"31","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R et al (2020) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan. China. Annal oncol 31(7):894\u2013901","journal-title":"China. Annal oncol"},{"key":"3341_CR17","unstructured":"24\/03\/2020 Keytruda-EMEA\/H\/C\/003820 - R\/0081. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-productinformation_en.pdf. Accessed 10 May 2020"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03341-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03341-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03341-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:55:08Z","timestamp":1629417308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03341-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03341-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"<b>PI:<\/b> Receipt of grants\/research supports: Astra Zeneca, BMS, Bayer, Lilly, Merck, Novartis, EISAI, Pfizer, MSD, AstraZeneca, Roche, Ipsen. Receipt of honoraria or consultation fees: Arbeitsgemeinschaft interdiziplin\u00e4re Medizin, Altana Health Service, AstaZeneca, Budosy, BMS, Bayer, DKG-Onkoweb, ESAI, EUSA, ID-Institut, Ipsen, Impulze, MedKom Acadamy, Merck, Medac, Medi-Seminar, MSD, MTE-Acadamy, New Concept Oncology, NGA-Acadamy, Novartis, Pfizer, Roche, Roche, StreamedUP!, Solution Acadamy, Onkowissen, Think Wired!. Participation in a company sponsored speaker\u2019s bureau: Not applicable. Stock shareholder: Not applicable. Spouse\/partner: Not applicable. Other support (please specify): Travel Expense: BMS, Byer, DKG, EUSA, Ipsen, Novartis, Merck, PharmaMar. <b>CG:<\/b> Receipt of grants\/research supports: Not applicable. Receipt of honoraria or consultation fees: Astellas, Astra Zeneca, BMS, EISAI, IPSEN, MSD, Merck Serono, Pfizer. Participation in a company sponsored speaker\u2019s bureau: Not applicable. Stock shareholder: Not applicable. Spouse\/partner: Not applicable. Other support (please specify): Travel Expense: Not applicable. <b>NK:<\/b> Receipt of grants\/research supports: Not applicable. Receipt of honoraria or consultation fees: Astellas, BMS, EISAI, EUSA, IPSEN, Jansen, MSD, Novartis, Pfizer. Participation in a company sponsored speaker\u2019s bureau: Not applicable. Stock shareholder: Not applicable. Spouse\/partner: Not applicable. Other support (please specify): Travel Expense: Aristo, BMS, Janssen, EUSA Pharma, MSD. <b>TG:<\/b> Receipt of grants\/research supports: Not applicable. Receipt of honoraria or consultation fees: Astra Zeneca, BMS, EISAI, IPSEN, MSD, Merck Serono, Novartis, Sanofi-Aventis, Pfizer, Roche. Participation in a company sponsored speaker\u2019s bureau: Not applicable. Stock shareholder: Not applicable. Spouse\/partner: Not applicable. Other support (please specify): Travel Expense: Not applicable. <b>MJ:<\/b> Receipt of grants\/research supports: Not applicable. Receipt of honoraria or consultation fees: BMS, Bayer, EISAI, EUSA, Hexal, Jansen, Merck Serono, Medac, MSD, Pfizer, Roche. Participation in a company sponsored speaker\u2019s bureau: Not applicable. Stock shareholder: Not applicable. Spouse\/partner: Not applicable. Other support (please specify): Travel Expense: Astellas, Bayer, Pfizer. <b>JB:<\/b> Receipt of grants\/research supports (inst.): Eisai, Ipsen, MSD, Novartis, Roche, Pfizer. Receipt of honoraria or consultation fees: AstraZeneca, Astellas, BMS, Eisai, Ipsen, MSD, Novartis, Roche, EUSA Pharma, Nektar, Pfizer. Participation in a company sponsored speaker\u2019s bureau: Not applicable. Stock shareholder: Not applicable. Spouse\/partner: Not applicable. Other support (please specify): Travel Expense (Inst.): BMS, Ipsen, Pfizer, Roche. <b>VG:<\/b> Receipt of grants\/research supports: Astra Zeneca, BMS, MSD, Ipsen, Novartis, Pfizer. Receipt of honoraria or consultation fees: Astra Zeneca, BMS, MSD, Ipsen, Novartis, pfizer, Merck Serno, EUSAPharm, EISAI, Roche, Bayer, Janssen-Vilag, Lilly, PharmaMar. Participation in a company sponsored speaker\u2019s bureau: Not applicable. Stock shareholder: Astra Zeneca, BMS, MSD. Spouse\/partner: Not applicable. Other support (please specify): Travel Expense: Astra Zeneca, BMS, Ipsen, Pfizer, Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}